Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protection - Top-Institutions - MDSpire

Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protection

  • By

  • Laura Marcos-Villar

  • Beatriz Perdiguero

  • Laura Sin

  • Enrique Álvarez

  • Sara Flores

  • José M. Casasnovas

  • Tirso Pons

  • Carlos Oscar S. Sorzano

  • Daniel del Hoyo

  • Philipp Lapuhs

  • María J. Alonso

  • Mariano Esteban

  • Carmen Elena Gómez

  • May 5, 2026

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center
    National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center

    Bethesda, MD

    Key Differentiators

    • Infectious Disease
    • Immunology

  • #2

    Mass General Brigham (Massachusetts General Hospital and Brigham and Women’s Hospital) with the Ragon Institute
    Mass General Brigham (Massachusetts General Hospital and Brigham and Women’s Hospital) with the Ragon Institute

    Boston, MA

    Key Differentiators

    • Infectious Disease
    • Immunology

  • #3

    Duke Human Vaccine Institute (DHVI), Duke University School of Medicine
    Duke Human Vaccine Institute (DHVI), Duke University School of Medicine

    Durham, NC

    Key Differentiators

    • Infectious Disease
    • Immunology

Original Source(s)

Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protection

  • by Laura Marcos-Villar, Beatriz Perdiguero, Laura Sin, Enrique Álvarez, Sara Flores, José M. Casasnovas, Tirso Pons, Carlos Oscar S. Sorzano, Daniel del Hoyo, Philipp Lapuhs, María J. Alonso, Mariano Esteban, Carmen Elena Gómez

  • May 5, 2026

Related Content

Prevalence, risk factors, and perceptions of vaccination against reproductive tract infections among urban females in Delhi: a cross-sectional study

Beyond recovery: long-term cardiovascular risks after severe COVID-19 requiring intensive care

Early-Phase Oral Antiviral Use and Post–COVID-19 Condition in Outpatients